• 1

    Gwadz RW, Carter R, Green I, 1979. Gamete vaccines and transmission-blocking immunity in malaria. Bull World Health Organ 57 (Suppl 1):175–180.

    • Search Google Scholar
    • Export Citation
  • 2

    Kaslow DC, 1996. Transmission-blocking vaccines. Hoffman SL, ed. Malaria Vaccine Development. Washington, DC: American Society for Microbiology Press, 181–228.

  • 3

    Carter R, Mendis KN, Miller LH, Molineaux L, Saul A, 2000. Malaria transmission-blocking vaccines: how can their development be supported? Nat Med 6 :241–244.

    • Search Google Scholar
    • Export Citation
  • 4

    Stowers A, Carter R, 2000. Current development in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1 :619–628.

  • 5

    Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Konigpward TF, Sinha R, Lupetti P, Beetsma AL, Rodriguez MC, Karras M, Hager A, Mendoza J, Butcher GA, Kafatos F, Janse CJ, Waters AP, Sinden RE, 2001. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 20 :3975–3983.

    • Search Google Scholar
    • Export Citation
  • 6

    Kaslow DC, Bathurst JC, Lensen T, Ponnudurai T, Barr PJ, Keister DB, 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62 :5576–5580.

    • Search Google Scholar
    • Export Citation
  • 7

    Hisaeda H, Stowers A, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC, 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 66 :6618–6623.

    • Search Google Scholar
    • Export Citation
  • 8

    Hisaeda H, Collins WE, Saul A, Stowers AW, 2002. Antibodies to Plasmodium vivax transmission-blocking vaccine do not show synergism. Vaccine 20 :763–770.

    • Search Google Scholar
    • Export Citation
  • 9

    Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabonkot JS, Torii M, Tsuboi T, Kumar N, 2004. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22 :3205–3213.

    • Search Google Scholar
    • Export Citation
  • 10

    Duffy PE, Kaslow DC, 1997. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as Plasmodium falciparum malaria transmission-blocking vaccine. Infect Immun 65 :74–76.

    • Search Google Scholar
    • Export Citation
  • 11

    Tsuboi T, Cao YM, Hitsumoto Y, Yanagi T, Kanabara H, Torii M, 1997. Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Infect Immun 65 :2260–2264.

    • Search Google Scholar
    • Export Citation
  • 12

    Tsuboi T, Kaslow D, Gozar M, Tachibana M, Cao Y, Torii M, 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 4 :772–782.

    • Search Google Scholar
    • Export Citation
  • 13

    Miles AP, Zhang Y, Saul A, Stowers AW, 2002. Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials. Protein Expr Purif 25 :87–96.

    • Search Google Scholar
    • Export Citation
  • 14

    Collins WE, Contacos PG, Krotoski WA, Howard WA, 1972. Transmission of four Central American strains of Plasmodium vivax. J Parasitol 58 :332–335.

    • Search Google Scholar
    • Export Citation
  • 15

    Malkin EM, Dubin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, 2005. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 :3131–3138.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 170 71 12
PDF Downloads 27 19 0
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

ASSESSMENT OF TRANSMISSION-BLOCKING ACTIVITY OF CANDIDATE Pvs25 VACCINE USING GAMETOCYTES FROM CHIMPANZEES

WILLIAM E. COLLINSMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by WILLIAM E. COLLINS in
Current site
Google Scholar
PubMed
Close
,
JOHN W. BARNWELLMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by JOHN W. BARNWELL in
Current site
Google Scholar
PubMed
Close
,
JOANN S. SULLIVANMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by JOANN S. SULLIVAN in
Current site
Google Scholar
PubMed
Close
,
DOUGLAS NACEMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by DOUGLAS NACE in
Current site
Google Scholar
PubMed
Close
,
TYRONE WILLIAMSMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by TYRONE WILLIAMS in
Current site
Google Scholar
PubMed
Close
,
AMY BOUNNGASENGMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by AMY BOUNNGASENG in
Current site
Google Scholar
PubMed
Close
,
JACQUELIN ROBERTSMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by JACQUELIN ROBERTS in
Current site
Google Scholar
PubMed
Close
,
ELIZABETH STROBERTMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by ELIZABETH STROBERT in
Current site
Google Scholar
PubMed
Close
,
HAROLD MCCLUREMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by HAROLD MCCLURE in
Current site
Google Scholar
PubMed
Close
,
ALLAN SAULMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by ALLAN SAUL in
Current site
Google Scholar
PubMed
Close
, and
CAROLE A. LONGMalaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia; Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland

Search for other papers by CAROLE A. LONG in
Current site
Google Scholar
PubMed
Close
Restricted access

Macaca mulatta monkeys were immunized with the candidate transmission-blocking vaccine against Plasmodium vivax, Pvs25, combined with alum or Montanide ISA 720. Efficacy was measured by combining post-immunization sera with gametocytes obtained from infections induced in chimpanzees using membrane-feeding techniques. The results indicate that immunization of M. mulatta monkeys with Pvs25 and Montanide ISA 720 was more effective than with alum in efficacy and resulted in the maintenance of a lasting transmission-blocking immunity to P. vivax. This was evident two weeks after the second immunization, and more strongly demonstrable 62 and 152 days after the second immunization. This transmission-blocking activity was strongly reinforced by a third immunization given 181 days after the primary immunization, as measured three weeks later by indirect membrane feeding. The use of gametocytes of P. vivax derived from infections induced in chimpanzees can contribute to the selection of appropriate constructs, formulations, and immunization regimens for the development of effective transmission-blocking vaccines.

Save